Efficacy and safety analysis of fenelidone combined with valsartan in the treatment of 1~3a stage chronic kidney disease with diabetes nephropathy
10.3760/cma.j.cn115807-20240312-00071
- VernacularTitle:非奈利酮联合缬沙坦治疗1~3a期慢性肾病伴糖尿病肾病的疗效和安全性分析
- Author:
Shenglin HE
1
;
Hui LI
;
Que YANG
Author Information
1. 陕西省人民医院内分泌糖尿病病院，西安 710068
- Publication Type:Journal Article
- Keywords:
Chronic kidney disease;
Phase 1 to 3a;
Diabetes kidney disease;
Valsartan;
Finelidone
- From:
Chinese Journal of Endocrine Surgery
2024;18(6):784-788
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of finelidone combined with valsartan in the treatment of 1-3a stage chronic kidney disease (CKD) with diabetic nephropathy (DKD) .Methods:A total of 100 cases with 1~3a stage CKD with DKD were divided into two groups by random number table method. The control group was treated by valsartan on the basis of conventional treatment, and the observation group was treated by valsartan combined with finelidone.Blood glucose [fasting blood glucose (FBG), glycated hemoglobin (HbAlc), 2h postmeal blood glucose (P2hBG) ], systolic blood pressure (SBP), renal function indicators [β2 microglobulin (β2-mg), 24h urinary protein quantity (24hUPr), blood creatinine (Scr), blood urea nitrogen (BUN) and blood potassium], inflammation indicators [C-reactive protein (CRP), high mobility group protein B1 (HMGB1) and transforming growth factor β1 (TGF-β1) ], oxidative stress markers [malondialdehyde (MDA), reactive oxygen species (ROS) and antioxidant superoxide dismutase (SOD), total antioxidant capacity (T-AOC) ] and adverse reactions was compared between two groups.Results:After treatment, the levers of FBG, HbAlc, P2hBG, SBP, β2-MG, 24hUPr, Scr, BUN, CRP, HMGB1, TGF-β1, MDA and ROS in the observation group were significantly lower than those in the control group ( P<0.05). The level of SOD and T-AOC in the observation group after treatment were (120.74±16.85) U/mL and (31.38±4.16) U/mL, respectively, significantly higher than (101.62±15.82) U/mL and (20.96±3.91) U/mL in the control group, and the differences were significant ( P<0.05). After treatment, the serum potassium level in the observation group was (4.16±0.62) mmol/L, and the incidence of adverse reactions was 8.00%, while that in the control group was (4.21±0.71) mmol/L, and the incidence of adverse reactions was 10.00%, with no significant difference between the two groups ( P>0.05) . Conclusion:Finelidone combined with valsartan can improve blood glucose and blood pressure of 1~3a stage CKD with DKD and protect renal function with good safety, which may be related to reducing oxidative inflammation and enhancing antioxidant capacity of the body.
